Summary:
John Maraganore launches City Therapeutics with $135 million in funding.
The startup focuses on RNA interference (RNAi) to develop new medicines.
CityRNAs will be used to target hard-to-reach tissues effectively.
John Maraganore Launches City Therapeutics
John Maraganore, the former CEO of Alnylam Pharmaceuticals, is back in the biotech scene with a new venture, City Therapeutics. This startup has successfully raised $135 million in funding from notable investors including ARCH Venture Partners, Fidelity, and Regeneron Ventures.
Innovation in RNA Interference
Based in Cambridge, Massachusetts, City Therapeutics aims to build on the success of Alnylam by developing innovative medicines that utilize RNA interference (RNAi) technology. This approach focuses on silencing specific genes to stop the production of harmful proteins, a concept that has gained traction since Alnylam's first RNAi treatment received regulatory approval in 2018.
The Next Step: CityRNAs
City Therapeutics plans to push the boundaries by targeting hard-to-reach tissues with advanced delivery vehicles and a novel class of smaller RNA molecules known as cleavage inducing tiny RNAs, or cityRNAs. This innovative approach is reflected in the startup's name and signifies a new wave of possibilities in RNA therapies.
Comments